Article Text

other Versions

PDF
Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis
  1. L G Moura1,
  2. R Tognon2,
  3. N S Nunes1,
  4. L Cataldi Rodrigues1,
  5. A F Ferreira1,
  6. S Kashima3,
  7. D T Covas3,4,
  8. M Santana5,
  9. E X Souto5,
  10. L Perobelli5,
  11. B P Simões4,
  12. M Dias-Baruffi1,
  13. F A Castro1
  1. 1Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
  2. 2Departamento de Farmácia, Universidade Federal de Juiz de Fora—Campus Governador Valadares, Governador Valadares, Minas Gerais, Brasil
  3. 3Hemocentro de Ribeirão Preto-Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
  4. 4Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil
  5. 5Hospital Estadual de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brasil
  1. Correspondence to L G Moura, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto 14040-903, São Paulo, Brasil; livia.moura{at}cemaden.gov.br

Abstract

Despite all the knowledge, the cellular and molecular mechanisms involved in myeloproliferative neoplasm (MPN) pathophysiology remain unclear. Authors have shown galectin-1 (Gal-1) and 3 playing roles in tumour angiogenesis and fibrosis, which were correlated with poor prognosis in patients with MPN. In the present study LGALS1 and LGALS3 were differently expressed between polycythemia vera, essential thrombocythemia (ET) and primary myelofibrosis (PMF) diseases. Increased LGALS3 expression was associated with a negative JAK2 V617F status mutation in leucocytes from PMF but not in patients with ET without this mutation. However, a positive Janus kinase 2 (JAK2) V617F cell line established from patients with ET (SET-2 cells) when treated with JAK inhibitor presented high levels of LGALS3. Additionally, high LGALS1 expression was found in CD34+ cells but not in leucocytes from patients with PMF, in absence of JAK2 V617F mutation, and also in SET-2 cells treated with JAK inhibitor. Thus, our findings indicate that differential expression of LGALS1 and/or LGALS3 in patients with MPN is linked with JAK2 V617F status mutation in these diseases and state of cell differentiation.

  • CANCER GENETICS
  • HAEMATO-ONCOLOGY
  • GENE AMPLIFICATION

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.